ZTI BIOSCIENCES
Monday, June 03, 2024
Company Presentation
![Other](https://cdn.asp.events/CLIENT_BIO_7BB99CBA_BAD1_B8C8_CF9F25DA29A80CC6/sites/BIOIC-2024/media/icons/seminars/blank.png)
Company Presentation Theater 1
ZTI BIOSCIENCES specializes in the development of radiopharmaceuticals for cancer therapeutics based on the Nano-tech platform (TERACARRIER™), distinguished as the world's first and only technology.
We are a drug delivery platform company that can deliver not only radiopharmaceuticals for treating diseases but also work with antibody-drug conjugates (ADCs) and immune-checkpoint inhibitors to target tumors with potentially higher efficacy, lower doses, and lower toxicity.
[Pipeline]
We are placing our focus on ZTI-201A, a formulation conjugated with Anti-HER2 for Ultra Low HER2 Expressing Cancer. Leveraging our proprietary technology, TERACARRIER™, ZTI-201A addresses the treatment challenges associated with Ultra Low HER2 Expressing Cancer, a condition with significantly fewer licensed drugs available.
[Business Model]
BM1) Validating TERACARRIER™ through IND
BM2) Licensing out pipelines and expanding them based on the TERACARRIER™ platform
BM3) Launching CDMO based on TERACARRIER™
![ZTI BIOSCIENCES](https://www.abstractscorecard.com/uploads/Tasks/upload/21754/XDQDGWMO-1775609-1-JPG.png)
Company Website:
http://zti-bio.com/
Lead Product in Development:
ZTI-201A (Lu-177, Anti-HER2, TERACARRIER)
Number Of Unlicensed Products (For Which You Are Seeking Partners):
3
Company HQ City
Zionsville
Company HQ State
Indianapolis
Company HQ Country
United States
CEO/Top Company Official
Jaden Hyungseok Chang
Development Phase of Primary Product
Pre-Clinical
Primary Speaker